Investigational drug · Phase 2
LY3871801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "LY3871801"
First trial start
2023
May 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY3871801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LY3871801" as an intervention, largest first.
- An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05848258 · 164 participants · Start May 23, 2023 · Primary completion Dec 8, 2025
Drug: LY3871801; Placebo · For: Rheumatoid Arthritis
Sites: Huntington Beach, California; Doral, Florida; Ocoee, Florida · 54 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05602675 · 39 participants · Start Nov 2, 2022 · Primary completion Mar 29, 2023
Drug: LY3871801; Methotrexate and 4 more · For: Healthy
Sites: Dallas, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT05960851 · 32 participants · Start Aug 9, 2023 · Primary completion Oct 25, 2023
Drug: LY3871801; Placebo · For: Healthy
Sites: Cypress, California
Eli Lilly and CompanyEli Lilly (LLY)
NCT05222399 · 15 participants · Start Feb 4, 2022 · Primary completion Mar 11, 2022
Drug: LY3871801 · For: Healthy
Sites: Singapore, Singapore
Eli Lilly and CompanyEli Lilly (LLY)
NCT06049108 · 8 participants · Start Sep 15, 2023 · Primary completion Nov 3, 2023
Drug: [14C]-LY3871801 · For: Healthy
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.